Printer Friendly
The Free Library
14,529,145 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Browse Non-Hodgkin's lymphomas topic

Subtopics (24)

 

Articles

1-100 out of 100 article(s)
Title Author Type Date Words
Allos Therapeutics Announces Issuance of U.S. Patent for FOLOTYN. Nov 30, 2009 520
Gloucester Pharmaceuticals to Present Positive Results from Multiple Studies of ISTODAX[R] at the ASH Annual Meeting. Nov 24, 2009 540
ImmunoGen, Inc. Announces Clinical Data Presentations on Three TAP Compounds at Upcoming ASH Annual Meeting and Exposition. Clinical report Nov 24, 2009 518
Novel therapeutic target for non-Hodgkin's lymphoma identified. Clinical report Nov 23, 2009 313
Seattle Genetics Initiates Phase I Clinical Trial of Antibody-Drug Conjugate SGN-75. Nov 16, 2009 705
Daily Wrap Up - Nov 16. Brief article Nov 16, 2009 286
United States : Allos Therapeutics awards NCCN a grant to evaluate pralatrexate. Nov 11, 2009 350
Allos Therapeutics to Present at Upcoming Conferences in November. Conference news Nov 10, 2009 402
ZEVALIN[R] Receives Positive Reimbursement Ruling Using Average Sales Price (ASP) Methodology. Nov 3, 2009 859
Eisai and TSD Japan Enter into a License and Joint Development Agreement of Denileukin Diftitox in Japan. Oct 26, 2009 746
Allos Therapeutics Announces U.S. Availability of FOLOTYN[TM] (pralatrexate injection) for Relapsed or Refractory Peripheral T-Cell Lymphoma. Oct 5, 2009 980
Malignant lymphoma of the testis: a study of 12 cases. Lantz, Andrea G.; Power, Nicholas; Hutton, Brian; Gupta, Rekha Clinical report Oct 1, 2009 3173
Allos Therapeutics' FOLOTYN[TM] First and Only FDA-Approved Therapy for Relapsed or Refractory Peripheral T-cell Lymphoma. Sep 25, 2009 1884
Research and Markets: Non-Hodgkin Lymphoma Therapy Area Pipeline Report. Report Sep 9, 2009 348
United States : FDA OKs Spectrum s Zevalin as blood-cancer treatment. Sep 5, 2009 249
United States : FDA Approves Ibritumomab Tiuxetanton as First-Line Therapy for Non-Hodgkin's Lymphoma. Sep 5, 2009 161
United States : Spectrum's ZEVALIN expanded label receives FDA approval for treating non-Hodgkin s Lymphoma. Sep 5, 2009 290
FDA Approves ZEVALIN[R] Expanded Label as Part of First-Line Therapy in Treatment of Follicular Non-Hodgkin's Lymphoma. Sep 4, 2009 1535
FDA Advisory Committee Recommends Gloucester Pharmaceuticals' Romidepsin for Approval for Cutaneous T-cell Lymphoma. Sep 2, 2009 592
Allos Therapeutics Announces FDA Advisory Committee Recommends Accelerated Approval of FOLOTYN[TM] (pralatrexate) for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma. Sep 2, 2009 1233
Allos Therapeutics to Hold Post Advisory Committee Conference Call. Sep 1, 2009 320
Gloucester Pharmaceuticals Completes $29 Million Financing. Aug 25, 2009 504
Gloucester Pharmaceuticals Announces FDA Advisory Committee Meeting to Discuss Romidepsin New Drug Application. Aug 17, 2009 335
Allos Therapeutics Announces FDA Advisory Committee to Review Pralatrexate for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma. Aug 10, 2009 472
YAUPON ENROLLS PHASE 2 OF CLEARAZIDE FOR T-CELL LYMPHOMA. Clinical report Aug 1, 2009 545
MALT lymphoma of the floor of the mouth: a case report. Gadre, Swarupa; Ryan, Matthew W.; Logrono, Roberto Aug 1, 2009 48
Systemic lupus erythematosus in a patient with primary MALT lymphoma of the larynx. Gonzalez, Nuria; Xicoy, Blanca; Olive, Alejandro; Jove, Josep; Ribera, Josep-Maria; Feliu, Evarist Aug 1, 2009 56
Allos Therapeutics Launches Peripheral T-Cell Lymphoma Website. Website overview Jul 23, 2009 676
Research and Markets: Lymphoma Drug Development Strategies at Work: New Report Includes Defined and Up to Date Development Strategies for 176 Lymphoma Therapeutic Drugs. Jul 17, 2009 380
Spectrum Pharmaceuticals Submitted Formal Response to FDA Complete Response Letter on Wednesday, July 8, 2009. Jul 9, 2009 919
Spectrum Pharmaceuticals Receives Complete Response Letter from FDA for Zevalin. Jul 5, 2009 742
Therapy-related hematological disorders following conventional chemotherapy for lymphoid malignancies in children. Spasova, Mariya Ivanova; Stoyanova, Angelina Asenova; Moumdjiev, Ivan Nikolov Report Jul 1, 2009 2886
Personalized Anti-Cancer Vaccine, BiovaxID[R], Targeting B-cell Lymphomas Available in Europe on a Named-Patient Basis. Clinical report Jun 28, 2009 1692
Gloucester Pharmaceuticals Presents Positive Clinical Data for Romidepsin in CTCL and Further Preclinical Evidence of Synergism with Bortezomib at ASCO. Clinical report Jun 1, 2009 1159
The Addition of VELCADE[R] (Bortezomib) for Injection to New and Standard Combinations Delivers Promising Results in Patients with Non-Hodgkin's Lymphoma. May 31, 2009 1557
Positive, Clinically Significant Phase III Results for Personalized Anti-Cancer Vaccine, BiovaxID[R], Presented at ASCO Plenary Session. Clinical report May 31, 2009 1721
Allos Therapeutics Reports Updated Data from Pivotol Phase 2 PROPEL Study of Pralatrexate at 45th ASCO Annual Meeting. May 30, 2009 1689
Gloucester Pharmaceuticals to Present New Data from Two Studies on Romidepsin at ASCO. Clinical report May 28, 2009 598
Allos Therapeutics Announces FDA Accepts Pralatrexate NDA for Filing and Grants the Application Priority Review Status. May 26, 2009 1128
SymBio Pharmaceuticals Limited and Eisai Co., Ltd. Conclude License Agreement for Bendamustine Hydrochloride (SyB L-0501) in Korea and Singapore. May 18, 2009 649
Allos Therapeutics Announces Updated Data from Pivotol Phase 2 PROPEL Study of Pralatrexate to be Presented at ASCO 2009. May 14, 2009 522
Wine may boost survival among non-Hodgkin's lymphoma patients. Apr 22, 2009 376
Allos Therapeutics Submits New Drug Application for Pralatrexate for Patients with Relapsed or Refractory Peripheral T-cell Lymphoma. Mar 25, 2009 1730
Allos Therapeutics' Pralatrexate Granted Orphan Medicinal Product Designation for the Treatment of Bladder Cancer by the European Commission. Mar 17, 2009 1069
Spectrum Pharmaceuticals Acquires 100% of ZEVALIN[R], an FDA-Approved, Proprietary, Biological Drug for Non-Hodgkin's Lymphoma. Mar 16, 2009 1788
Allos Therapeutics Announces Final Results from Pivotal PROPEL Trial of Pralatrexate in Patients with Peripheral T-cell Lymphoma. Feb 3, 2009 1912
ZEVALIN[R] Produced 83 Percent Complete Response Rate in Mucosa-Associated Lymphoid Tissue (MALT) Orbital Lymphoma Study. Jan 22, 2009 1370
FDA approves Genzyme's Mozobil for use in combination with G-CSF for treating patients with NHL and MM blood cancers. Jan 1, 2009 343
Cell Therapeutics Exercises Its Option to Sell Interest in Zevalin Joint Venture to Spectrum Pharmaceuticals. Jan 1, 2009 718
"I healed myself from mantle cell NHL with Gerson therapy". Joyce Letter to the editor Jan 1, 2009 209
FDA Approves Genzyme's Mozobil. Dec 15, 2008 1620
Gloucester Pharmaceuticals Announces Positive Results from Phase 1/2 Multiple Myeloma Clinical Trial at ASH. Financial report Dec 9, 2008 1020
Gloucester Pharmaceuticals Announces Positive Results from Romidepsin T-cell Lymphoma Clinical Trials at ASH. Financial report Dec 8, 2008 1749
ZEVALIN Consolidation in First-Line Therapy in Patients with Non-Hodgkin's Lymphoma Resulted in a Progression-Free Survival of Greater Than 67 Months. Dec 8, 2008 1566
Seattle Genetics Reports Objective Responses with Dacetuzumab in Phase II Non-Hodgkin Lymphoma Trial. Dec 6, 2008 995
Two Pralatrexate Studies Presented at the 50th Annual Meeting of the American Society of Hematology. Dec 6, 2008 1414
Combination Cancer Therapy is Focus of $1M Merck Research Grant Received by NCCN. Dec 2, 2008 824
FDA APPROVES CEPHALON TREANDA TO TREAT NON-HODGKINS LYMPHOMA. Dec 1, 2008 1022
Spectrum Pharmaceuticals Announces ZEVALIN sBLA Granted Priority Review by the FDA; Target Decision (PDUFA) Date of April 2, 2009. Dec 1, 2008 1638
U.S. FDA Grants Pralatrexate Orphan Drug Designation for the Treatment of Patients with Diffuse Large B-Cell Lymphoma. Nov 24, 2008 900
Gloucester Pharmaceuticals to Present Positive Results from Multiple Romidepsin Clinical Trials at the ASH Annual Meeting. Nov 20, 2008 686
RECRUITMENT COMPLETED IN OFATUMUMAB NHL PIVOTAL STUDY. Nov 1, 2008 390
Biovest and IDIS Announce Agreement to Launch Named-Patient Program for Anti-Cancer Vaccine in Europe. Oct 29, 2008 1445
FDA Grants Full Approval to ONTAK' (denileukin diftitox) For Use in Patients with Cutaneous T-Cell Lymphoma (CTCL). Oct 16, 2008 539
Biovest Announces BiovaxID(R) Anti-Cancer Vaccine Prolongs Cancer-Free Survival by 44%. Oct 7, 2008 2298
Angiogenic non-Hodgkin T/natural killer (NK)-cell lymphoma: report of three cases. Martins-Filho, Rubens A.; Demarco, Ricardo C.; Valera, Fabiana C.P.; Shaletich, Catarina; Felix, Pau Clinical report Oct 1, 2008 2130
Pacific Ridge School said its education assistance fund has received a contribution from Richard and Kaye Woltman to honor their daughter, Melisa, who died in 2002 from non-Hodgkin's lymphoma. Glazer, Joyce Brief article Sep 15, 2008 62
Radiotherapy-associated euthyroid Graves ophthalmopathy following floor-of-mouth surgery: a case report. Jaber, James J.; Thomas, Frank J.; Carfrae, Mathew J.; Galati, Lisa T. Clinical report Sep 1, 2008 2225
WALES: Cancer charity hails drug success. Aug 16, 2008 183
Returning home to care for a dying mother: a nurse spends ten months caring for her dying mother at home. Though an incredibly difficult and painful experience, she believes it has made her a better, more empathetic nurse. Polglaze, Tracey Aug 1, 2008 2983
An unusual fluid. The advantages of cross discipline training. Gibbs, G.; Read, K.M. Aug 1, 2008 1579
Biovest Announces Conference Call / Webcast to Discuss Phase 3 BiovaxID(R) Anti-Cancer Vaccine Results. Jul 21, 2008 838
Biovest Reports Results for Patients Treated with Anti-Cancer Vaccine: BiovaxID(R) Demonstrates Clinically and Statistically Significant Improvement of Disease-Free Survival in Non-Hodgkin's Lymphoma in Pivotal Phase 3 Clinical Trial. Financial report Jul 17, 2008 1194
Clinical Data For REVLIMID(R) And VIDAZA(R) In Important Blood Cancers Presented at The 13th European Hematology Association Congress. Jun 17, 2008 2305
Preliminary Results from International Study Report That REVLIMID(R) Provides Responses for Patients with Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma. Report Jun 14, 2008 536
Biovest Reports Blinded Results for Phase 3 Study Evaluating Anti-Cancer Vaccine, BiovaxID(R), which Shows 100% Difference in Disease-Free Survival at 36 Months in the Comparative Arms. Jun 11, 2008 812
Seattle Genetics Reports Final SGN-40 Phase I Non-Hodgkin Lymphoma Data at International Conference on Malignant Lymphoma. Conference news Jun 5, 2008 965
Gloucester Pharmaceuticals Announces Podium Presentation of Positive Results from Phase 2b Registration Trial of Romidepsin in Refractory CTCL. Financial report Jun 5, 2008 1061
Allos Therapeutics Announces Interim Data from Phase 1 Study of PDX in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma. Jun 5, 2008 1169
Seattle Genetics Announces Initiation of SGN-40 Phase Ib Clinical Trial in Combination With Velcade for Multiple Myeloma. Jun 2, 2008 829
Investigational Studies Highlight Potential Utility of Zevalin Radioimmunotherapy in Stem Cell Transplantation for Non-Hodgkin's Lymphoma. Jun 1, 2008 604
Who Will Benefit from Growth in the European NHL Therapeutics Market? Industry overview May 21, 2008 305
Gloucester Pharmaceuticals Announces Positive Results from Phase 2b Registration Trial of Romidepsin in Refractory CTCL. Financial report May 19, 2008 1047
Allos Therapeutics Reports Interim Response and Safety Data from Pivotal Phase 2 PROPEL Trial. May 15, 2008 1862
NCCN Updates Non-Hodgkin's Lymphoma Guidelines. Apr 22, 2008 607
Allos Therapeutics Completes Patient Enrollment in Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma. Apr 22, 2008 1317
Biovest Reports that Independent Data Monitoring Committee Recommends Unblinding of Phase 3 Clinical Results for its Anti-Cancer Vaccine, BiovaxID(R). Apr 17, 2008 1539
Accentia Announces that After Reviewing Unblinded Results, Independent DMC Recommends Presenting Data on BiovaxID(R) to FDA and Worldwide Regulatory Agencies in Order to Seek Marketing Approvals for Follicular Non-Hodgkin's Lymphoma. Apr 17, 2008 2101
ZIOPHARM Presents Positive Data from Phase II Study of Darinaparsin in Advanced Hematological Malignancies at AACR 2008 Annual Meeting. Apr 16, 2008 664
Seattle Genetics Announces Initiation of Phase Ib Clinical Trial of SGN-40 in Combination with Rituxan and Gemzar for Non-Hodgkin Lymphoma. Apr 8, 2008 785
Extramedullary plasmacytoma presenting as a nasal mass in an immunosuppressed patient: treatment after failed primary radiotherapy. Dempewolf, Ryan; Lee, John H. Case study Apr 1, 2008 1520
Cancer drug hopes. Feb 28, 2008 177
InNexus Biotechnology Announces Second Preclinical CandidateDXL702 (HER2/neu) Targeting Breast Cancer. Feb 19, 2008 797
InNexus Biotechnology Announces Preliminary Results of Animal Study Comparing Cancer Killing Activity of Its DXL625 (CD20) Treatment for Non-Hodgkin's Lymphoma With Leading Marketed Product. Feb 7, 2008 712
Uptake of Rituxan in the Maintenance Setting for Follicular Lymphoma (FL) Has Allowed the Drug to Achieve Further Market Penetration. Feb 1, 2008 436
Marginal-zone B-cell lymphoma of the bony palate presenting as sinusitis. Ayers, Lisa Skultety; Oxenberg, Jacqueline; Zwillenberg, Seth; Ghaderi, Mahmoud Disease/Disorder overview Jan 1, 2008 1763
Rosetta Columbia University Medical Center to develop microRNA-based diagnostics for leukemia and non hodgkin lymphoma. Nov 1, 2007 687
Radiological case of the month: Vani Vijayakumar, MD; Raman Kansal, MD; and Atiar Rahman, MD, PhD. Vijayakumar, Vani; Kansal, Raman; Atiar, Rahman Case study Jul 1, 2007 746
Radiological case of the month: Pramod Gupta, MD; Qing Hua Zhao, MD; Mark Rosovsky, MD; Ashok Madan, MD. Gupta, Pramod; Zhao, Qing Hua; Rosovsky, Mark; Madan, Ashok Case study May 1, 2005 683
Results favorable for B-cell non-Hodgkin's lymphoma. Nov 1, 1998 190

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles